The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.
Alexander Xenakis
Consultant or Advisory Role - Gilead Sciences
Nathaniel Smith
Consultant or Advisory Role - Gilead Sciences
Rachel Beckerman
Consultant or Advisory Role - Gilead Sciences
Jagpreet Chhatwal
Consultant or Advisory Role - Gilead Sciences
Stephanie A. Gregory
Consultant or Advisory Role - Gilead Sciences
Javier Pinilla-Ibarz
Consultant or Advisory Role - Gilead Sciences
Andrew Briggs
Consultant or Advisory Role - Gilead Sciences